Literature DB >> 8674789

Activity of nadifloxacin against methicillin-resistant Staphylococcus aureus isolated from skin infections: comparative study with seven other fluoroquinolones.

S Nishijima1, M Nakagawa, N Tsuboi, H Akamatsu, T Horio, M Fujita, S Kawabata.   

Abstract

The in vitro susceptibility of methicillin-resistant Staphylococcus aureus (MRSA) to nadifloxacin and seven other fluoroquinolones (norfloxacin, ofloxacin, enoxacin, ciprofloxacin, lomefloxacin, tosufloxacin and sparfloxacin) was evaluated. The MRSA isolates were isolated from 114 skin infections between 1991 and 1994. Nadifloxacin exhibited the lowest minimum inhibitory concentration and there were no MRSA isolates resistant to nadifloxacin, while there were some resistant to all of the other seven fluoroquinolones. The minimum concentrations of these drugs needed to cause 50% inhibition of the isolates increased dramatically from 1991 to 1992, but has hardly changed since 1992.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8674789     DOI: 10.1177/030006059602400102

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  3 in total

Review 1.  Ofloxacin otic solution: a review of its use in the management of ear infections.

Authors:  K L Simpson; A Markham
Journal:  Drugs       Date:  1999-09       Impact factor: 9.546

2.  Antistaphylococcal activity of WCK 771, a tricyclic fluoroquinolone, in animal infection models.

Authors:  Mahesh V Patel; Noel J De Souza; Shrikant V Gupte; Mohammad A Jafri; Sachin S Bhagwat; Yati Chugh; Habil F Khorakiwala; Michael R Jacobs; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

3.  In vitro activity of the new quinolone WCK 771 against staphylococci.

Authors:  Michael R Jacobs; Saralee Bajaksouzian; Anne Windau; Peter C Appelbaum; Mahesh V Patel; Shrikant V Gupte; Sachin S Bhagwat; Noel J De Souza; Habil F Khorakiwala
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.